Videos

Colorectal Cancer: Managing Recurrent Disease

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the role of biosimilars in the treatment of breast cancer.

Robert "Bo" Gamble, director of Strategic Practice Initiatives, Community Oncology Alliance (COA), discusses some of the exciting topics that will be covered during the upcoming 2018 Community Oncology Conference. 

James Hamrick, MD, senior medical director, Flatiron Health, discusses how clinical trials can be improved in the community setting during the ACCC 44th Annual Meeting & Cancer Center Business Summit.

Experts in the gynecologic oncology field share their key takeaways from the 2018 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, held at the Hyatt Regency Resort & Convention Center in New Orleans, Louisiana, from March 24 to 27, 2018.

Miguel-Angel Perales, MD, deputy chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, discusses what experts are expecting to change in the treatment landscape of non-Hodgkin’s lymphoma in the next year. Perales says by the end of 2018, there may be 3 CAR T-cell therapies approved for the treatment of non-Hodgkin’s lymphoma.

Jaron Mark, MD, gynecologic oncology fellow at Roswell Park Comprehensive Cancer Center, discusses findings from a restrictive protocol that limited the number of opioids prescribed after gynecologic surgeries. Patients looked at in this trial had undergone ambulatory or minimally invasive procedures. 

Akihito Kawazoe, MD, discussed the safety and efficacy results of the phase I/II SCOOP trial of napabucasin plus pembrolizumab for treatment of patients with metastatic colorectal cancer.

Ira Winer, MD, PhD, assistant professor in the the Division of Gynecologic Oncology at Wayne State University, discusses the outlook on immunotherapy in the treatment landscape of gynecologic cancers. 

Relapsed Follicular Lymphoma

Managing Relapsed Follicular Lymphoma

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha-targeting antibody-drug conjugate, with pembrolizumab (Keytruda) in patients with platinum-resistant epithelial ovarian cancer.